We analyzed approximately 20,000 patients with DM and MAFLD using a large-scale epidemiologic cohort and compared approximately 6,500 well-balanced pairs of new users of SGLT2 or DPP4 inhibitors with propensity score matching. The gene discussed is DPP4; the disease is diabetes mellitus.